Download as PDF, PPTX
More Related Content
Similar to HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize pharma perspective_Antti Haapalinna
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize pharma perspective_Antti Haapalinna
- 1. Orion’s new strategyand industry trends seen from a midsize pharma perspective Professor Antti Haapalinna, PhD, eMBA Head of External Science and Partnering Vice President, R&D
- 2. This presentation containsforward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of these strategies. These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forward-looking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation. Disclaimer 2
- 3. Agenda 3 1. Orion inbrief 2. Industry trends? 3. Orion’s strategy
- 4.
- 5. Orion at aglance (2020 figures) Orion Corporation Presentation Net sales Operating profit Personnel R&D investments 6 production sites in Finland Own sales unit in 26 European countries, Singapore, Malaysia, Thailand and Australia 1,078 MEUR 280 MEUR 3,311 123 MEUR Established in 1917 5 Orion has operations in 30 countries (Europe and Asia)
- 6. Proprietary Products SpecialtyProducts Animal Health Fermion & Contract manufacturing June 2021 Orion Corporation Presentation 6 Orion’s businesses 350 351 357 406 444 2016 2017 2018 2019 2020 Net sales MEUR 508 519 473 486 493 2016 2017 2018 2019 2020 Net sales MEUR 77 76 80 86 89 2016 2017 2018 2019 2020 Net sales MEUR 81 84 65 71 74 2016 2017 2018 2019 2020 Net sales MEUR 39% 46% 8% 7% = share of Group net sales in 2020 In-house developed drugs and other drugs with valid product protection for global markets. Own sales network in Europe. Generic prescription drugs, OTC and non-medicinal products, biosimilars. Finland 56% Scandinavia 16% Eastern Europe 14% ROW 14% Own animal drugs for global markets. Other drugs and well-being products. Own sales network in the Nordics and Eastern Europe. Active pharmaceutical ingredients (APIs) for own proprietary products. CMO & CDMO services for other pharma companies.
- 7. What are thepharmaceutical industry trends?
- 8. 13 September 2021 Presenter / Department8 Consumer • Population aging • Health awareness intensifying • Demand for personalised therapy increasing, big disease will be fragmented (Precision medicine) • Service concepts broadening • New distribution channels emerging • Private spend on medicines increasing Technology • R&D productivity more challenging • Role of biologicals has increased • Alternative technologies emerging (paradigm shift from managing diseases to curing diseases. Curative therapies such as cell and gene therapies) • Digitalization /E-commerce opportunities broadening (AI, Real-world data, Real-world evidence, Digital therapeutics...) World has become and is becoming more complex ...
- 9. 13 September 2021 Presenter / Department9 Socio-economic • Economic downturn still influencing • Role of innovations as growth driver increasing • Number of generic launches increasing • Growth in emerging markets increasing • Competition intensifying • Numerous market specific payer actions emerging Regulatory • Price regulations increasing • Reimbursement requirements increasing • Scrutiny on drug efficacy and safety intensifying • Time span of regulatory processes extending World has become and is becoming more complex ...
- 10.
- 11. 11 Challenges • Obsolescence ofcurrent products and services • Traditional business models become outdated • Devaluation of current organizational capabilities • New, unknown or unexpected competitors Opportunities • New levels of engagement with customers (sales vs customer data) • More valuable relationships – contribution to societies • New creative partnerships and alliances Medicine as a service
- 12.
- 13.
- 14. Strategic growth target:Net sales EUR 1.5 billion in 2025 Financial objectives: Growing net sales more rapidly than growth of the pharma market. Achievement of this objective requires continuous investment in development of the product portfolio. ≥ Keeping the equity ratio at least 50%. > Maintaining profitability at a good level. The aim is operating profit that exceeds 25% of net sales. € Distributing an annual dividend that in the next few years will be at least EUR 1.30 per share, and increasing the dividend in the long term. Orion’s strategic growth target and financial objectives Investor Presentation © Orion Corporation
- 15. Deliver late-stage portfolio Build portfolio Maximize value ofassets R&D- Translating world-class science into novel life-changing therapies Our mission is to make new medicines for the patients with unmet need Building the growth for Orion 15 - Invent and find the medicinal targets and molecules and develop them as medicines to humans and animals - Look collaborations and partner ships for new technologies Get marketing authorizations for the developed products and globally together with partners Support the growth of marketed products in new territories and with additional studies Compliance and availability of products on the markets
- 16. 16 Key changes inOrion R&D 1 2 4 1 Research strengthened to drive target identification and validation 2 Resources re- allocated for the prioritized projects 3 Focused clinical trials on biomarker selected patients 4 Support pipeline with in-licensing and partnering 5 Boosting generics development 6 Microbiome research in Animal Health Science & Data driven organisation • Focused strategy in Oncology and Neurological Diseases Build a balanced pipeline with continuous feed of clinical projects Increase success rate and speed AREAS TO DEVELOP R&D- Translating world-class science into novel life-changing therapies
- 17. 17 Orion Corporation signsEuropean wide marketing and distribution agreement with Marinus Pharmaceuticals for ganaxolone PRESS RELEASE 3 AUGUST 2021 https://www.orion.fi/en/Orion-group/media/press-releases/2021/orion-corporation-signs-european-wide-marketing-and-distribution-agreement-with-marinus-pharmaceuticals-for-ganaxolone/?epieditmode=true Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy PRESS RELEASE 9 JUNE 2021 https://www.orion.fi/en/Orion-group/media/press-releases/2021/orions-clinical-trial-shows-significant-improvement-for-chronic-pain-patients-using-virtual-reality-therapy/?epieditmode=true Orion Animal Health’s Tessie® (tasipimidine) receives positive CVMP opinion PRESS RELEASE 21 JUNE 2021 https://www.orion.fi/en/Orion-group/media/press-releases/2021/orion-animal-healths-tessie-tasipimidine-receives-positive-cvmp-opinion/?epieditmode=true A few public examples of this year R&D- Translating world-class science into novel life-changing therapies
- 18. 18 Chimeric Antigen ReceptorT-cell therapy as an example of personalised therapy Three approved CAR T-cell therapies with excellent response rates for hematological cancers Gene manipulated cells is the Product R&D- Translating world-class science into novel life-changing therapies
- 19. 19 Orion Corporation andthe Finnish Red Cross Blood Service have concluded an agreement on research collaboration with the aim of developing chimeric antigen receptor (CAR) T-cell therapy https://www.orion.fi/en/Orion-group/media/press-releases/2021/-orion-and-the-blood-service-launch-collaboration-to-develop-new-car-t-cell-cancer-therapy/?epieditmode=true PRESS RELEASE 8 JUNE 2021 The Blood Service has considerable experience in cell research, in the supply of cord blood and stem cell grafts classified as tissue products, and in the preparation of ATMP cell products classified as medicinal products. The Blood Service also has expertise and the necessary clean rooms for the research and high-quality production of therapeutic cells. R&D- Translating world-class science into novel life-changing therapies
- 20. 20 Orion Corporation andAlligator Bioscience announce immuno-oncology research collaboration and license agreement PRESS RELEASE 18 AUGUST 2021 https://www.orion.fi/en/Orion-group/media/press-releases/2021/orion-corporation-and-alligator-bioscience-announce-immuno-oncology-research-collaboration-and-license-agreement/ Fig from: Huang, S., van Duijnhoven, S.M.J., Sijts, A.J.A.M. et al. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. J Cancer Res Clin Oncol 146, 3111–3122 (2020) Bispecific antibody will be developed based on the Alligator's proprietary bispecific antibody format Alligator’s role is to design, generate and ensure good quality of antibodies Orion’s role is in vitro and in vivo characterization to enable candidate nomination, clinical development by Orion Bispecific antibodies provide as a tool many advantages for the next generation immuno-oncology treatments with improved efficacy, particularly in the cancer patients who do not respond to the present available therapeutic R&D- Translating world-class science into novel life-changing therapies
- 21. 21 To be successfulnow and in the future Exploit - Deliver portfolio - Maximize value of assets Explore - Build portfolio and new services - New Partnerships - New Technologies - New ecosystems At the same time is needed: * Focused strategy * Innovation and creativity * Goal directed actions * Acceptance of changes * Cost effectiveness * Tolerance for failures